


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Inter Patent Application of

HAYNES et al

Serial No. 10/753,339

Filed: January 9, 2004

For: HUMAN IMMUNODEFICIENCY VIRUS VACCINE

Confirmation No. 7106

Atty. Ref.: 1579-880

Group: 1648

Examiner: Stucker, J.J.

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 20, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each
identified document (as may be required) and a translation or a
concise explanation of each non-English language document (such
as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - ☐ a) The required Statement made in item 8 below; or
 - ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
 - ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

HAYNES et al
Serial No. 10/753,339
April 20, 2005

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

1579-880

10/753,339

APPLICANT


HAYNES et al

FILING DATE

GROUP

January 9, 2004

1648



(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	20010036461	11/2001	Haynes et al			
	20040132010	7/2004	Haynes et al			
	20020086283	7/2002	Haynes et al			
	20040039172	2/2004	Haynes et al			
	20040197344	10/2004	Haynes et al			
	2004086506	5/2004	Haynes et al			
	2004001851	1/2004	Haynes et al			
	20030147888	8/2003	Haynes et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 2004/075850	9/2004	WIPO			
WO 2005/016952	2/2005	WIPO			
WO 2004/009785	1/2004	WIPO			
WO 03/046137	6/2003	WIPO			
WO 2005/028625	3/2005	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	U.S. Provisional Application No. 60/503,460 filed September 17, 2003 and U.S. Provisional Application No. 60/604,722 filed August 27, 2004 (see attached copy of WO 2005/028625)
	U.S. Patent Application No. 10/518,523 filed December 21, 2004 (U.S. National Phase of WO 2004/009785 see above)
	U.S. Patent Application No. 10/973,977 filed October 27, 2004
	U.S. Patent Application No. 10/973,475 filed October 27, 2004
	U.S. Provisional Application No. 60/625,720 filed November 8, 2004
	Oscherwitz et al, "A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein", Vaccine 17:2392-2399 (1999)
	Borbe et al, "Structural and Immunological Reactivity of the Principal Neutralizing Determinant V3 of Glycoprotein gp120 of HIV-1", Journal of Peptide Science 1:109-123 (1995)
	Winchell et al, "Mucosal Immune Response to an HIV C4/V3 Peptide Following Nasal or Intestinal Immunization of Rabbits", AIDS Research and Human Retroviruses 13(10):881-889 (1997)
	Kelleher et al, "Safety and Immunogenicity of UBI HIV-1MN Octameric V3 Peptide Vaccine Administered by Subcutaneous Injection", AIDS Research and Human Retroviruses 13(1):29-32 (1997)
	DATABASE Geneseq 'Online!', 12 May 1999, "T cell epitope/MHC ligand SEQ ID NO:226.", retrieved from EBI accession no. GSN:AAY10296, Database accession no. AAY10296 & WO 99/02183 A (Simard John J L; CTL Immunotherapies Corp (CA); Kuendig Thomas M (CH)) 21 January 1999- XP002303500

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No.

Serial No.

1579-880

10/753.339

Applicant

HAYNES et al

Filing Date

~~TC/A.U.~~

January 9, 2004

U.S. PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	DATABASE Geneseq 'Online!, 14 September 1999, "HIV-derived lipopeptide epitope GAG253 for mixed micelles.", retrieved from EBI accession no. GSN:AA Y26615 Database accession no. AAY26615 & WO 99/27954 A (Gras Masse Helene; Guillet Jean Gerard (FR); Inst. Nat. Sante Rech. Med) 10 June 1999 - XP002303503
	DATABASE Geneseq 'Online!, 22 February 2000, "HLA-A2-binding HIV-1 GP41 CTL epitope #250, retrieved from EBI accession no. GSN:AA Y66448 Database accession no. AAY66448 & WO 99/49893 A (Univ Boston) 7 October 1999 - XP002303504
	Gao et al, "Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID networks for HIV isolation and characterization", Journal of Virology, The American Society for Microbiology 70(3):1651-1667 (1996)
	DATABASE Geneseq 'Online!, 12 November 1990, "Peptide component of AIDS vaccine.", retrieved from EBI accession no. GSN:AAP82469 Database accession no. AAP82469 & EP 0 273 716 A (US Health) 6 July 1988 - XP002303505
	DATABASE USPTO Proteins 'Online!, 7 October 1996, "Sequence 17 from patent US 5519114.", retrieved from EBI accession no. USPOP:AAB13195 Database accession no. AAB13195 & US 5 519 114 A (Johnson Howard M et al) 21 May 1996 - XP002303506
	DATABASE EPO Proteins 'Online!, 26 April 1994, "antigen which binds to antibodies with an affinity for HIV-1 p24", retrieved from EBI accession no. EPOP:A18855 Database accession no. A18855 & WO 91/13360 A (Replico Medical AB) 5 September 1991 - XP002303507
	DATABASE EPO Proteins 'Online!, 26 April 1994, "antigen which binds to antibodies with an affinity for HIV-1 p24", retrieved from EBI accession no. EPOP:A18953 Database accession no. A18953 & WO 91/13360 A (Replico Medical AB) 5 September 1991 - XP002303508
	DATABASE EPO Proteins 'Online!, 14 July 1993, "Human immunodeficiency virus gag protein", retrieved from EBI accession no. EPOP:A04294 Database accession no. A04294 & WO 86/02383 A (Centre Nat. Rech. Scient. Pasteur Institut (FR)) 24 April 1986 - XP002303509
	DATABASE EPO Proteins 'Online!, 23 August 1995, "Cytotoxic T lymphocyte epitope 19 derived from gag p17 (MA) protein.", retrieved from EBI accession no. GSN:AAR68762 Database accession no. AAR68762 & WO 94/28871 A (Endocon Inc) 22 December 1994 - XP002303510

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.